Nanoparticle-Mediated Cuproptosis and Photodynamic Synergistic Strategy: A Novel Horizon for Cancer Therapy

IF 3.1 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-01-27 DOI:10.1002/cam4.70599

Junrui Zhang, Anren Zhang, Yibing Guo, Guoliang Miao, Shengchang Liang, Jie Wang, Junhong Wang

{"title":"Nanoparticle-Mediated Cuproptosis and Photodynamic Synergistic Strategy: A Novel Horizon for Cancer Therapy","authors":"Junrui Zhang, Anren Zhang, Yibing Guo, Guoliang Miao, Shengchang Liang, Jie Wang, Junhong Wang","doi":"10.1002/cam4.70599","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Photodynamic therapy (PDT) is a noninvasive cancer treatment that works by using light to stimulate the production of excessive cytotoxic reactive oxygen species (ROS), which effectively eliminates tumor cells. However, the therapeutic effects of PDT are often limited by tumor hypoxia, which prevents effective tumor cell elimination. The oxygen (O<sub>2</sub>) consumption during PDT can further exacerbate hypoxia, leading to post-treatment adverse events.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>This review aims to explore the potential of cuproptosis, a recently discovered copper-dependent form of programmed cell death, to enhance the anticancer effects of PDT. Cuproptosis is highly dependent on mitochondrial respiration, specifically the tricarboxylic acid (TCA) cycle, and can increase O<sub>2</sub> and ROS levels or decrease glutathione (GSH) levels, thereby improving PDT outcomes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The review discusses the latest research advancements in the field, detailing the mechanisms that regulate cuproptosis and PDT. It also explores how nanoparticle (NP)-based strategies can be used to exploit the synergistic potential between cuproptosis and PDT. The article examines the prospects of synergistic anticancer activity guided by nanodelivery systems, which could overcome the challenges associated with hypoxia in cancer treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The combination of cuproptosis and PDT, facilitated by NP-based delivery systems, presents a promising approach to enhance the effectiveness of cancer therapy. The review concludes by discussing the challenges and future research directions for this combination therapy, highlighting the need for further investigation into the mechanisms and optimization of treatment strategies to improve outcomes in cancer treatment.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 3","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770888/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70599","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Photodynamic therapy (PDT) is a noninvasive cancer treatment that works by using light to stimulate the production of excessive cytotoxic reactive oxygen species (ROS), which effectively eliminates tumor cells. However, the therapeutic effects of PDT are often limited by tumor hypoxia, which prevents effective tumor cell elimination. The oxygen (O₂) consumption during PDT can further exacerbate hypoxia, leading to post-treatment adverse events.

Objectives

This review aims to explore the potential of cuproptosis, a recently discovered copper-dependent form of programmed cell death, to enhance the anticancer effects of PDT. Cuproptosis is highly dependent on mitochondrial respiration, specifically the tricarboxylic acid (TCA) cycle, and can increase O₂ and ROS levels or decrease glutathione (GSH) levels, thereby improving PDT outcomes.

Methods

The review discusses the latest research advancements in the field, detailing the mechanisms that regulate cuproptosis and PDT. It also explores how nanoparticle (NP)-based strategies can be used to exploit the synergistic potential between cuproptosis and PDT. The article examines the prospects of synergistic anticancer activity guided by nanodelivery systems, which could overcome the challenges associated with hypoxia in cancer treatment.

Conclusions

The combination of cuproptosis and PDT, facilitated by NP-based delivery systems, presents a promising approach to enhance the effectiveness of cancer therapy. The review concludes by discussing the challenges and future research directions for this combination therapy, highlighting the need for further investigation into the mechanisms and optimization of treatment strategies to improve outcomes in cancer treatment.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纳米粒子介导的铜化和光动力协同策略：癌症治疗的新领域。

背景：光动力疗法（PDT）是一种非侵入性的癌症治疗方法，其工作原理是利用光刺激产生过量的细胞毒性活性氧（ROS），从而有效地消除肿瘤细胞。然而，PDT的治疗效果往往受到肿瘤缺氧的限制，这阻碍了肿瘤细胞的有效清除。PDT期间的氧气消耗可进一步加剧缺氧，导致治疗后不良事件。目的：本综述旨在探讨铜增生（一种新近发现的依赖铜的程序性细胞死亡形式）增强PDT抗癌作用的潜力。铜protosis高度依赖于线粒体呼吸，特别是三羧酸（TCA）循环，可以增加O2和ROS水平或降低谷胱甘肽（GSH）水平，从而改善PDT的预后。方法：综述了该领域的最新研究进展，详细介绍了铜突起和PDT的调控机制。它还探讨了如何利用纳米颗粒（NP）为基础的策略来开发铜沉积和PDT之间的协同潜力。本文探讨了纳米递送系统指导下协同抗癌活性的前景，该系统可以克服癌症治疗中与缺氧相关的挑战。结论：在以np为基础的给药系统的促进下，铜protosis和PDT的结合是一种有希望提高癌症治疗有效性的方法。本文最后讨论了该联合治疗的挑战和未来的研究方向，强调需要进一步研究机制和优化治疗策略以改善癌症治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.